Gene therapy for ocular hypertension using hfCas13d-mediated mRNA targeting
PNAS Nexus · 02.06.2025 · 4 (6)
DOI: 10.1093/pnasnexus/pgaf168 ↗Kurz gefasst
Fachartikel in der Zeitschrift PNAS Nexus, online erschienen am 17.06.2025. Verfasst von Siyu Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Stanford University School of Medicine, 1651 Page Mill Road, Rm 2220, Palo Alto, CA 94304, USA. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Children's Health Research Institute, International Retinal Research Foundation, NIH.
Abstract (Originalsprache)
Glaucoma is a major global cause of irreversible vision loss. It is marked by elevated intraocular pressure (IOP) and the loss of retinal ganglion cells (RGC). While there are medical and surgical therapies for glaucoma aiming to reduce aqueous humor production or enhance its drainage, these treatments are often inadequate for effectively managing the disease. In this study, we developed a targeted therapy for glaucoma by knocking down two genes associated with aqueous humor production (aquaporin 1 [AQP1] and carbonic anhydrase type 2 [CA2]) using Cas13 RNA editing systems. We demonstrate that hfCas13d-mediated knockdown of AQP1 and CA2 significantly lowers IOP in wild-type mice and in a corticosteroid-induced glaucoma mouse model. We show that the lowered IOP results from decreasing aqueous production without affecting the outflow facility; this treatment also significantly promotes RGC survival as compared with untreated control groups. Therefore, CRISPR–Cas-based gene editing may be an effective treatment to lower IOP for glaucomatous optic neuropathy.
Autor:innen und Institutionen
- Department of Ophthalmology, Stanford University School of Medicine, 1651 Page Mill Road, Rm 2220, Palo Alto, CA 94304, USA.
- Department of Medicine, John A. Burns School of Medicine, 651 Ilalo St, Honolulu, HI 96813, USA.
- Department of Ophthalmology, Palo Alto Veterans Administration, 3801 Miranda Ave, Palo Alto, CA 94305, USA.
ORCID-Profile: Siyu Chen, Zhiquan Liu, Qing Wang, Ke Ning, Qi Zhang, Jingyu Zhao, Yang Sun
Förderung
- Children's Health Research Institute
- International Retinal Research Foundation
- NIH
Zitieren
APA
Chen, S., Liu, Z., Lo, C. H., Wang, Q., Ning, K., Zhang, Q., Zhao, J., Shen, Y., & Sun, Y. (2025). Gene therapy for ocular hypertension using hfCas13d-mediated mRNA targeting. PNAS Nexus, 4(6). https://doi.org/10.1093/pnasnexus/pgaf168
Vancouver
Chen S, Liu Z, Lo CH, Wang Q, Ning K, Zhang Q, et al. Gene therapy for ocular hypertension using hfCas13d-mediated mRNA targeting. PNAS Nexus. 2025;4(6). doi:10.1093/pnasnexus/pgaf168
BibTeX
@article{Chen2025,
author = {Chen, Siyu and Liu, Zhiquan and Lo, Chien-Hui and Wang, Qing and Ning, Ke and Zhang, Qi and Zhao, Jingyu and Shen, Yingchun and Sun, Yang},
title = {Gene therapy for ocular hypertension using hfCas13d-mediated mRNA targeting},
journal = {PNAS Nexus},
year = {2025},
volume = {4},
number = {6},
doi = {10.1093/pnasnexus/pgaf168}
}
EUVIMED